HART AKI
Acute Kidney Injury Risk Prediction
Key Facts
About Prevencio
Prevencio is a private, commercial-stage diagnostics company leveraging artificial intelligence and multi-analyte biomarker panels to revolutionize cardiovascular disease testing. Its core HART tests are designed to address significant unmet needs in emergency medicine and cardiology by improving diagnostic accuracy over traditional single-biomarker tests and imaging, potentially reducing unnecessary procedures and costs. The company has seven tests on the market, supported by publications and key opinion leader endorsements, and is targeting the massive global cardiovascular disease market. Its business model is focused on commercializing these proprietary blood tests to healthcare providers and patients.
View full company profile